ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,427.13
-2.31%
US Tech 100
18,615.20
-3.17%
Dow Jones
39,853.87
-1.25%
Brent Oil
80.735
-0.05%
Bitcoin
65,279.37
-0.98%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Biomea Fusion Inc (BMEA)

  7. Biomea Fusion Inc (BMEA) News

BMEA

Biomea Fusion (BMEA)

Biomea Fusion Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BMEA
DateTimeSourceHeadlineSymbolCompany
06/13/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
06/12/20245:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
06/12/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
06/07/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
06/06/20244:05PMGlobeNewswire Inc.Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical HoldNASDAQ:BMEABiomea Fusion Inc
06/03/20244:05PMGlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
05/30/20249:12AMGlobeNewswire Inc.Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 DiabetesNASDAQ:BMEABiomea Fusion Inc
05/02/20244:05PMGlobeNewswire Inc.Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
05/01/20244:10PMGlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
04/01/20244:10PMGlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
04/01/20249:02AMGlobeNewswire Inc.Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219NASDAQ:BMEABiomea Fusion Inc
04/01/20249:00AMGlobeNewswire Inc.Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
03/07/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
03/06/20243:04AMGlobeNewswire Inc.Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionNASDAQ:BMEABiomea Fusion Inc
03/01/20244:16PMGlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
02/12/20245:00PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BMEABiomea Fusion Inc
01/18/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
01/18/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
01/10/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
01/09/202411:02AMGlobeNewswire Inc.Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BMEABiomea Fusion Inc
01/08/20249:00AMGlobeNewswire Inc.Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219NASDAQ:BMEABiomea Fusion Inc
01/05/20244:02PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BMEABiomea Fusion Inc
01/02/20244:05PMGlobeNewswire Inc.Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BMEABiomea Fusion Inc
12/11/20239:25AMGlobeNewswire Inc.Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASHNASDAQ:BMEABiomea Fusion Inc
12/09/20235:30PMGlobeNewswire Inc.Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose CohortsNASDAQ:BMEABiomea Fusion Inc
12/08/20239:00AMGlobeNewswire Inc.Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin ResistaNASDAQ:BMEABiomea Fusion Inc
12/07/20239:15AMGlobeNewswire Inc.Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular DiseNASDAQ:BMEABiomea Fusion Inc
12/05/20238:30AMGlobeNewswire Inc.Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 DiabetesNASDAQ:BMEABiomea Fusion Inc
11/27/20238:30AMGlobeNewswire Inc.Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024NASDAQ:BMEABiomea Fusion Inc
11/16/20238:30AMGlobeNewswire Inc.Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular DiseaseNASDAQ:BMEABiomea Fusion Inc
 Showing the most relevant articles for your search:NASDAQ:BMEA

Your Recent History

USOTC
KEGS
1812 Brewing (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
RXMD
Progressive Care (QB)
USOTC
ITUP
Interups (CE)
USOTC
RSPI
RespireRx Pharmaceuticals (CE)
USOTC
ENZC
Enzolytics (PK)
USOTC
RONN
Ronn Motor (PK)
NASDAQ
NVDA
NVIDIA
USOTC
HIRU
Hiru (PK)
AMEX
SPY
SPDR S&P 500
NASDAQ
TSLA
Tesla
NYSE
AMC
AMC Entertainment
USOTC
RDGL
Vivos (QB)
USOTC
IFUS
Impact Fusion (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
BLEG
Branded Legacy (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved